“Nothing else matches the consistency, quality and concentration of RNA that I get from these kits.” – Asha Palat, department of biology and biochemistry at the University of Houston
The World Health Organization estimates that a startling one in four people worldwide is infected with tuberculosis. Learn how the Omani government is pioneering
#TB
Management.
#EndTB
#StopTB
“Treating latent TB means fewer drugs, fewer side effects, and shorter times for therapy.” - Dr. Eskild Petersen, Ministry of Health, Oman | Learn how ⬇️
A pioneer in the field of immunotherapy discovers and manipulates specific immune cells to defend against cancer using QIAGEN’s next-generation sequencing technologies:
“This strategic step with Thermo Fisher will enable us to enter a promising new era and will give our employees the opportunity to have an even greater impact." - Thierry Bernard, interim CEO of QIAGEN N.V. and SVP, head of the molecular diagnostics business area
“My research targets ways to monitor the immune responses of cancer patients treated with anti PD-1 antibodies, as well as the best selection of T-cells for adoptive cell transfer.” - Nathalie Labarrière, French Institute of Health and Medical Research, University of Nantes.
We are adding additional staff to support the highest-priority production of QIAamp, QIAstat-Dx, QIAsymphony and EZ1 products. For timely updates, bookmark this page:
“We hope to provide more definitive identification, whether it´s a person of interest in a terrorist attack or the victim of a crime or a missing person case.” – Dr. Sheree Hughes, University of Queensland
24-hour, seven-day-a-week operations at our manufacturing sites: Over the last two months we have already increased sample prep and nCoV-related output by approximately 70%. We are dramatically ramping up production capacity to help address this public health crisis.
#COVID19
We are ramping up production at manufacturing sites in Hilden, Germany and Barcelona, Spain, moving to three shifts that will work seven days a week, hiring new staff, and using manufacturing capacity at a Maryland facility in the US.
I just received this email from one of the largest hospitals in MA
@BrighamWomens
, calling for donations of RNA isolation kits. “We have all of the elements we need to launch the test except for viral RNA isolation kits.“
@QIAGEN
@Roche
: Please help!🙏
Learn how Dr. Eskild Petersen, a world-renowned
#TB
expert from Denmark, consults in Oman to spearhead the fight against the world's deadliest infectious disease
#StopTB
#EndTB
@michaelmina_lab
@CDCgov
1 | At this point we have not seen any near-term impacts from the coronavirus outbreak on supplies of materials and components.
@michaelmina_lab
@CDCgov
2 | However, extraordinary demand for coronavirus testing workflows, which include QIAGEN products, is challenging our capacity for certain items and may lead to backorders with delayed delivery or reduced allocation of affected products.
#COVID19
#coronavirus
We are seeking fast FDA approval for our panel: “Our objective was to bring the test as soon as possible to the US hospitals, to the US potential patients, because, we are in an emergency.” – Thierry Bernard, Interim CEO at QIAGEN
Ramping up production of kits for testing the
#COVID19
virus. These are intense times for all of us, and with new cases showing up across the globe, the need for rapid diagnostics is rising.
#coronavirus
📢 The new kit detects the novel coronavirus SARS-CoV-2 and adds rapid Sample to Insight syndromic testing to QIAGEN’s portfolio of molecular testing solutions in the public health emergency.
#COVID
ー19
“My research targets ways to monitor the immune responses of cancer patients treated with anti PD-1 antibodies, as well as the best selection of T-cells for adoptive cell transfer.” - Nathalie Labarrière, French Institute of Health and Medical Research, University of Nantes.
Getting enough information from touch DNA on samples such as weapons, explosives and degraded remains is incredibly challenging. Forensic scientists, like Dr. Sheree Hughes, are improving ways to get more genetic information from less sample using QIAGEN DNA quantification kits.
First syndromic testing solution to obtain CE marking as an in vitro diagnostic (“IVD”) for the detection of SARS-CoV-2 , and is now available for purchase in the European Union
#COVID19
In order to fight the
#Coronavirus
in the U.S.,
@QIAGEN
is shipping tests to America this week. $QGEN CEO Thierry Bernard joins
@megtirrell
to discuss the tests and what the company is doing to combat the pandemic on
@CNBC
.
We are supporting several existing LDT protocols by providing testing components and mid- to high-throughput automation solutions: follow the link for full list ⬇️
#covid19
#covid_19
#coronavirus
#COVID19
Since the onset of the outbreak, we have ramped up our efforts in helping healthcare workers curb the spread of the disease.
MSNBC´s film team experienced first-hand at our German headquarters how testing with the QIAstat-Dx works:
Shipping first “QIAstat-Dx Respiratory 2019-nCoV Panel” prototype cartridges for clinical performance assessment in China and Europe. Kudos to the team for quickly making progress on the pathway to deliver a syndromic solution for testing of the new
#coronavirus
strain in Feb.!
"We begin making QIAstat-Dx SARS-CoV-2 test kits available in the U.S. as the first syndromic test to detect SARS-CoV-2 and also a range of more than 20 other respiratory targets."
- Thierry Bernard, CEO QIAGEN Full press release:
@michaelmina_lab
@CDCgov
3 | We are actively managing all aspects of our supply chain, striving to meet all the needs in the most timely way possible. We are highly committed to supporting you and the public health agencies involved in the global response to this emergency.
Supporting Japan in the fight against
#COVID19
: 10,000 detection kids have arrived. Kits are used for testing cruise ship passengers and travelers from Wuhan. We´ll increase the production of kits for
#Japan
.
📢 QIAGEN and INOVIO expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO’s VGX-3100 for advanced cervical dysplasia
It might be sunny outside, but still: Teams all over the world are working 24/7 to keep increasing the number of kits available for
#COVID19testing
.
Pictured here is one of our production teams in the US.
Their message: We are here for you! So please
#StayHome
To all customers: We have scaled up production dramatically and we are working together with you to assess your flexibility, timing + quantity needs. We are providing ongoing product supplies into the US. Please contact your sales rep and bookmark
Meet one of our EZ1 production teams in Hilden, Germany. Their message to you: We’re here for you, 24/7!
Please be there for them too and
#StayHome
. We’re
#StrongerTogether
#FlattentheCurve
#COVID19
For updated information, please visit
We are providing ongoing product supplies to the U.S., a focal point in recent testing concerns, and other countries. For customers facing delays or allocations, we are offering alternative workflow solutions. For more information:
“
#TB
is a dangerous disease, but it’s curable. It’s a pity that people are still dying from
#tuberculosis
, and I believe we can better manage this disease.“ – Amadou Gueye
QIAreach™ SARS-CoV-2 Antigen Test, developed in partnership with Ellume, is an important step towards decentralized mass screening by processing samples in 2–15 minutes.
We are responding as quickly as possible to provide solutions to contain the spread of the coronavirus, a situation that the WHO has declared an international public health emergency.
#COVID19
QIAGEN to continue successful growth strategy focused on execution and greater value creation after voluntary public takeover offer falls short. Full press release:
QIAGEN is proud to partner with the
@moma_dk
in the large scale genomic surveillance of SARS-CoV-2 in Denmark. Monitoring the development of mutations is essential in this fight.
#b1117
#Pathalogy
Time is precious in the daily life of a pathologist:
↗️ number of samples rises
↘️ time to deliver facts is cut
➡️ efficiency is measured in seconds saved.
#SampleToInsight
#GeneReaderNGS
We are gaining BARDA funding for the approval process of QIAstat-Dx test kit for SARS-CoV-2 coronavirus. Follow this link for more updates on how we are responding to
#COVID19
⬇️
“Just as our QIAGEN teams are working 24/7 to ensure production we know we can rely upon
@UPS
as our partner to make sure these kits and components arrive on time and in the right condition to where they’re needed most." - Barthold Piening, SVP, Head of Global Operations
We are partnering with
@QIAGEN
to deliver nucleic acid extraction kits critical to COVID-19 testing, as well as its novel QIAstat-Dx Coronavirus testing cartridges to destinations around the world.
#healthcare
#logistics
Dr. Metin Colpan, co-founder, former CEO and Managing Director of QIAGEN, has been nominated as a finalist for the
#InventorAward
2021 by
@EPOorg
in the lifetime achievement category.
Please join us in casting your vote for Dr. Colpan here ➡️
🎉 We are excited to announce our partnership with
@penn_state
University, aimed at shaping research, education, and outreach in microbiomes. Learn more 👉
This is a message from our field application specialists: We are here for you!
In this instance, a QIAGEN team of field application specialists (FAS) used Zoom to quickly get everything installed and ready to run for COVID-19 testing.
#StrongerTogether
Emily recently celebrated her 18th birthday, a milestone that seemed impossible when she was diagnosed with cancer at age 5. After treatments failed twice, a groundbreaking therapy was found.
Join her journey and discover how
@EWhiteheadFdn
is supporting other cancer patients.
"It was absolutely shocking. I kept asking, ‘Are you sure?’ I just couldn’t believe it because I had not been near anybody with
#TB
.“ – Laura Hall, Vermont, USA
“The first thing I will do when this crisis is over is sit together with all my children for a meal and give the grandchildren lots of kisses. Then visit my mother in Sicily.”
“We are really ramping up efforts, as we did in Europe, as we did in Asia-Pacific, to meet that challenging timeline and bring the solution to the US hospitals as soon as possible.” – Thierry Bernard, Interim CEO at QIAGEN
#COVID19
A new test out of
@QIAGEN
can deliver results in just one hour. The
#medtech
community is working 24/7 in this global fight against
#COVID19
. Great work, QIAGEN!
We are pleased to announce the acquisition of
@NofOne
to expand our clinical bioinformatics capabilities in molecular oncology decision support. Their Insights reporting tools and MarkerMine database will be integrated into our QCI portfolio.
Ramping up testing also means ramping up production of instruments. “Zollner has more than doubled the production of instruments for QIAGEN. And demand is further increasing.” 1/7 Thread ⬇️
#nobelprize2020
Congratulations! The Nobel Prize in Chemistry 2020 was awarded jointly to Emmanuelle Charpentier and Jennifer A. Doudna "for the development of a method for genome editing."
We plan to launch a novel straightforward approach to viral RNA epidemiology that will significantly simplify and accelerate PCR analysis and remove key testing bottlenecks for SARS-CoV-2 and other RNA viruses.
The rapid portable test that can detect SARS-CoV-2 antigens in people with active infections in less than 15 minutes and process on average around 30 swab samples per hour using a small digital detection system.
#FightCOVID19
#WorldMicrobiomeDay
🕹️ We´ll reprint the famous “Gut check – the microbiome game”. Play this online game, submit your score at the end to enter the raffle:
News: First
#FDA
-approved companion diagnostic for PIK3CA biomarkers to enhance precision medicine in
#breastcancer
➡️ guiding treatment decisions from tissue and
#liquidbiopsy
for newly approved therapy PIQRAY® (alpelisib) from Novartis
➡️
Over 30 European partners are presenting their progress at the 4th
#SPIDIA4P
Consortium Meeting hosted by QIAGEN in Hilden. The Horizon2020 project promotes the
#standardisation
of pre-analytical workflows applied to
#personalisedmedicine
, ultimately improving global healthcare.
Congratulations!
#NobelPrize2019
in Physiology or Medicine has been awarded jointly to William G. Kaelin, Jr, Peter J. Ratcliffe and Gregg L. Semenza “for their discoveries of how cells sense and adapt to oxygen availability.”
Awesome
#Customers
📷Oxford University/
@NobelPrize